Does the FDA warn about any HRT side effects

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA.gov, hormone therapy carries a range of potential side effects, from mild and manageable to less common but more serious risks that depend on age, health history, and which hormones are used. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

Common FDA-listed side effects

• Breast tenderness: A feeling of fullness or soreness, similar to pre-menstrual tenderness.
• Bloating or fluid retention: Mild swelling in the abdomen, hands, or feet.
• Nausea: Usually improves with food or switching the dose or formulation.
• Headaches: May occur as the body adjusts to hormones.
• Vaginal spotting or bleeding: Especially during the first few months of therapy.

Less common but important FDA warnings

• Blood clots: According to FDA-approved prescribing information, estrogen taken by mouth may slightly increase the risk of clots in the legs or lungs. Transdermal estrogen (patch, gel, spray) has a much lower clot risk.
• Stroke: According to FDA Drug Safety Communication, a small increase in stroke risk is noted mainly in older women who start hormone therapy after age 60.
• Heart attack: According to FDA.gov, risk is mainly associated with starting oral estrogen later in life; starting near menopause is associated with lower risk, though a qualified prescriber should evaluate individual circumstances.
• Breast cancer: According to FDA-approved prescribing information, a small increased risk has been noted when estrogen is combined with progestin for several years. Estrogen alone, in women without a uterus, does not carry this same pattern.
• Gallbladder disease: According to FDA.gov, oral estrogen may increase the chance of gallstones or gallbladder inflammation.

Why these warnings exist

According to the WHI, these risks were identified in older, large studies that used higher-dose, oral hormones. Modern clinical practice often uses lower doses and transdermal estrogen, which may reduce many of these risks. According to NAMS, the warnings remain in place so that every patient and clinician may make an informed choice based on individual risk factors.

What this means for you

• Individual risk varies: According to ACOG, hormone therapy started around menopause and reviewed regularly by a qualified prescriber may be appropriate for many women depending on their health history.
• Formulation matters: According to FDA-approved prescribing information, transdermal estrogen and micronized progesterone are generally associated with fewer certain risks compared to oral formulations.
• Regular check-ins with a qualified prescriber help ensure the dose and route remain appropriate over time.

These warnings highlight areas to monitor so that hormone therapy decisions may be made with full awareness of potential risks. A qualified prescriber should guide all treatment decisions.